H.C. Wainwright raised the firm’s price target on Celcuity (CELC) to $66 from $50 and keeps a Buy rating on the shares following the Q2 report. The firm expects a gedatolisib new drug application submission and clinical data updates before year end.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELC:
- Celcuity’s Geda Triplet Therapy Shows Promising Phase III Results, Justifying Buy Rating
- Celcuity’s Strong Prospects: Buy Rating Affirmed Amidst Positive Drug Developments and Robust Financial Position
- Celcuity Inc. Reports Promising Q2 2025 Results
- Celcuity reports Q2 EPS (93c), consensus (85c)
- Celcuity’s Promising Clinical Trial Results and Strong Buy Recommendation by Andrew Berens